<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809835</url>
  </required_header>
  <id_info>
    <org_study_id>0708002943</org_study_id>
    <secondary_id>R01DA015969-13</secondary_id>
    <nct_id>NCT00809835</nct_id>
  </id_info>
  <brief_title>Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse</brief_title>
  <official_title>Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are testing to see if Galantamine, a learning enhancing medication, will help methadone
      maintained cocaine abusers with their learning and memory specific to CBT using an innovative
      CBT computer program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are proposing a randomized double blind clinical trial of galantamine and our innovative
      computer-assisted version of CBT, alone and in combination, to improve treatment outcome and
      cognitive functioning among cocaine users. The proposed study will be the first to evaluate a
      cognitive enhancing medication as a means of enhancing the effects of an extremely promising
      empirically validated behavioral therapy for addiction, and hence bridge cognitive
      neuroscience and behavioral therapies development.

      The aim is to conduct a 12 week randomized placebo controlled trial, using a 2x2 factorial
      model, that will evaluate the efficacy of adding computer assisted training in CBT
      (&quot;CBT4CBT&quot;) and galantamine to standard treatment for 160 cocaine abusing or dependent
      methadone-maintained individuals. Participants will be randomized to (1) standard treatment
      (TAU) plus placebo, (2) TAU plus galantamine, (3) TAU plus CBT4CBT plus placebo, or (4) TAU
      plus CBT4CBT plus galantamine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction in cocaine use, operationalized as the frequency of cocaine use by month using timeline followback.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cocaine Abstinence</measure>
    <time_frame>12 weeks</time_frame>
    <description>operationalized by percentage of drug-free urine specimens submitted (We will use the Branan ToxCup Drug Screen Cup onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepine, and opioids) at 12 Weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>12 weeks</time_frame>
    <description>A composite using a carefully selected neuropsychological battery that includes measures of executive cognitive functioning frequently affected among cocaine users, likely to be important moderators of CBT4CBT, and sensitive to galantamine effects. These will include measures of multiple aspects of attention, cognitive inhibition, sustained attention (CANTAB), decision making (BART), and memory (digit span).
Scores ranged from -1.77 to 1.42 with a higher score indicating higher cognitive functioning.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Standard Treatment As Usual (TAU)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU Plus Galantamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU plus CBT plus galantamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>Daily 8 mg galantamine capsule</description>
    <arm_group_label>TAU Plus Galantamine</arm_group_label>
    <arm_group_label>TAU plus CBT plus galantamine</arm_group_label>
    <other_name>Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Computer Assisted Cognitive Behavioral Therapy (CBT)</intervention_name>
    <description>CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.</description>
    <arm_group_label>TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)</arm_group_label>
    <arm_group_label>TAU plus CBT plus galantamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between ages of 18 and 50

          -  Enrolled in RNP methadone program and stable on methadone for at least 3 weeks

          -  Current cocaine abuse or dependence according to DSM-IV criteria

          -  No current medical problems and normal ECG

          -  If female, not currently pregnant or breast feeding and using reliable birth control

          -  Fluent in English and have at least a 6th grade reading level

          -  Can commit to 12 weeks of treatment and are willing to be randomized

        Exclusion Criteria:

          -  Current major psychiatric illness including mood, psychotic or anxiety disorder

          -  History of major medical illnesses including asthma, chronic obstructive lung disease,
             gastrointestinal ulcer, hepatic or renal impairment, cardiac rhythm disturbances

          -  Use of medications including beta blockers and NASAIDs

          -  Known allergy to Galantamine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Carroll, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinsella Treatment Center (KTC)</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Network of Programs</name>
      <address>
        <city>Stratford</city>
        <state>Connecticut</state>
        <zip>06615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <results_first_submitted>August 4, 2016</results_first_submitted>
  <results_first_submitted_qc>May 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2017</results_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>Methadone</keyword>
  <keyword>CBT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be available to other researchers upon request. Please contact Dr. Carroll</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Galantamine and CBT</title>
          <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine Behavioral: Computer Assisted Cognitive Behavioral Therapy (CBT) CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.</description>
        </group>
        <group group_id="P2">
          <title>Galantamine Only</title>
          <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine</description>
        </group>
        <group group_id="P3">
          <title>Placebo and CBT</title>
          <description>TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Only</title>
          <description>Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Galantamine and CBT</title>
          <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine
Behavioral: Computer Assisted Cognitive Behavioral Therapy (CBT) CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.</description>
        </group>
        <group group_id="B2">
          <title>Galantamine</title>
          <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine</description>
        </group>
        <group group_id="B3">
          <title>Placebo and CBT</title>
          <description>Computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Only</title>
          <description>Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.04" spread="8.72"/>
                    <measurement group_id="B2" value="38.70" spread="10.79"/>
                    <measurement group_id="B3" value="39.82" spread="8.99"/>
                    <measurement group_id="B4" value="36.30" spread="9.41"/>
                    <measurement group_id="B5" value="38.36" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial/Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use</title>
        <description>Reduction in cocaine use, operationalized as the frequency of cocaine use by month using timeline followback.</description>
        <time_frame>12 weeks</time_frame>
        <population>Presented are data for those measured at baseline and at 12 weeks. 2 individuals in the Galantamine arm were not measured at 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Galantamine and CBT</title>
            <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine
Behavioral: Computer Assisted Cognitive Behavioral Therapy (CBT) CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.</description>
          </group>
          <group group_id="O2">
            <title>Galantamine</title>
            <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine</description>
          </group>
          <group group_id="O3">
            <title>Placebo and CBT</title>
            <description>Computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Only</title>
            <description>Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use</title>
          <description>Reduction in cocaine use, operationalized as the frequency of cocaine use by month using timeline followback.</description>
          <population>Presented are data for those measured at baseline and at 12 weeks. 2 individuals in the Galantamine arm were not measured at 12 weeks.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.82" spread="8.68"/>
                    <measurement group_id="O2" value="14.81" spread="9.05"/>
                    <measurement group_id="O3" value="15.68" spread="7.78"/>
                    <measurement group_id="O4" value="14.85" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.60" spread="6.95"/>
                    <measurement group_id="O2" value="6.32" spread="6.52"/>
                    <measurement group_id="O3" value="7.65" spread="7.41"/>
                    <measurement group_id="O4" value="10.25" spread="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Abstinence</title>
        <description>operationalized by percentage of drug-free urine specimens submitted (We will use the Branan ToxCup Drug Screen Cup onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepine, and opioids) at 12 Weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>Three arm had one subject drop out before study medication was given- therefore the number analyzed are those that received first treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Galantamine and CBT</title>
            <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine
Behavioral: Computer Assisted Cognitive Behavioral Therapy (CBT) CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.</description>
          </group>
          <group group_id="O2">
            <title>Galantamine</title>
            <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine</description>
          </group>
          <group group_id="O3">
            <title>Placebo and CBT</title>
            <description>Computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Only</title>
            <description>Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Abstinence</title>
          <description>operationalized by percentage of drug-free urine specimens submitted (We will use the Branan ToxCup Drug Screen Cup onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepine, and opioids) at 12 Weeks</description>
          <population>Three arm had one subject drop out before study medication was given- therefore the number analyzed are those that received first treatment.</population>
          <units>percentage of negative urines</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.45" spread="35.62"/>
                    <measurement group_id="O2" value="31.13" spread="34.16"/>
                    <measurement group_id="O3" value="20.49" spread="27.60"/>
                    <measurement group_id="O4" value="14.78" spread="19.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Function</title>
        <description>A composite using a carefully selected neuropsychological battery that includes measures of executive cognitive functioning frequently affected among cocaine users, likely to be important moderators of CBT4CBT, and sensitive to galantamine effects. These will include measures of multiple aspects of attention, cognitive inhibition, sustained attention (CANTAB), decision making (BART), and memory (digit span).
Scores ranged from -1.77 to 1.42 with a higher score indicating higher cognitive functioning.</description>
        <time_frame>12 weeks</time_frame>
        <population>All participants did not complete the CANTAB assessments at both pre and post treatment. Reasons for not completing were refusal to complete the tasks, inability to complete the tasks in a manner in which they could be scored and equipment or computer problems.</population>
        <group_list>
          <group group_id="O1">
            <title>Galantamine and CBT</title>
            <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine
Behavioral: Computer Assisted Cognitive Behavioral Therapy (CBT) CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.</description>
          </group>
          <group group_id="O2">
            <title>Galantamine</title>
            <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine</description>
          </group>
          <group group_id="O3">
            <title>Placebo and CBT</title>
            <description>Computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Only</title>
            <description>Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Function</title>
          <description>A composite using a carefully selected neuropsychological battery that includes measures of executive cognitive functioning frequently affected among cocaine users, likely to be important moderators of CBT4CBT, and sensitive to galantamine effects. These will include measures of multiple aspects of attention, cognitive inhibition, sustained attention (CANTAB), decision making (BART), and memory (digit span).
Scores ranged from -1.77 to 1.42 with a higher score indicating higher cognitive functioning.</description>
          <population>All participants did not complete the CANTAB assessments at both pre and post treatment. Reasons for not completing were refusal to complete the tasks, inability to complete the tasks in a manner in which they could be scored and equipment or computer problems.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.12" spread=".58"/>
                    <measurement group_id="O2" value=".11" spread=".50"/>
                    <measurement group_id="O3" value="-.06" spread=".71"/>
                    <measurement group_id="O4" value=".03" spread=".49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Galantamine and CBT</title>
          <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine
Behavioral: Computer Assisted Cognitive Behavioral Therapy (CBT) CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.</description>
        </group>
        <group group_id="E2">
          <title>Galantamine</title>
          <description>Drug: Galantamine Daily 8 mg galantamine capsule
Other Names:
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine</description>
        </group>
        <group group_id="E3">
          <title>Placebo and CBT</title>
          <description>Computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Only</title>
          <description>Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Medical hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Inpatient Substance Use Treatment Hospitalization</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Inpatient Psychiatric Hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="14" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>indigestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea or Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood in Stool</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Loss of Appetite</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen M. Carroll, Ph.D., Albert E Kent Professor of Psychiatry</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203.937.3486 ext 7403</phone>
      <email>kathleen.carroll@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

